Molecular Biomarker-Defined Brain Tumors: Epidemiology, Validity, and Completeness in the United States

alexandrossfakianakis shared this article with you from Inoreader Molecular Biomarker-Defined Brain Tumors: Epidemiology, Validity, and Completeness in the United States Via Neuro-Oncology Advance Access Abstract Background Selected molecular biomarkers were incorporated into U.S. cancer registry reporting for patients with brain tumors beginning in 2018. We investigated the completeness and validity of these variables, and described the epidemiology of molecularly-defined brain tumor types. Methods Brain tumor patients with histopathologically-confirmed diagnosis in 2018 were identified within the Central Brain Tumor Registry of the United States and NCI's Surveillance, Epidemiology, and End Results Incidence databases. The brain molecular markers (BMM) site-specific data item was assessed for coding completeness and validity. 1p/19q status, MGMT promoter methylation, and WHO grade data items, and new ICD-O-3 codes were additionally evaluated. These data were used to profile the characteristics and age-adjusted incidence rates per 100,000 population of molecularly-defined brain tumors with 95% confidence intervals (95%CI). Results BMM completeness across the applicable tumor types was 75-92% and demonstrated favorable coding validity. IDH-wildtype glioblastomas' incidence rate was 1.74 (95%CI: 1.69-1.78), as compared to 0.14 for WHO grade 2 (95%CI: 0.12-0.15), 0.15 for grade 3 (95%CI: 0.14-0.16), and 0.07 for grade 4 (95%CI: 0.06-0.08) IDH-mutant astrocytomas. Irrespective of WHO grade, IDH mutation prevalence was highest in adolescent & young adult patients and IDH-mutant astrocytomas were more frequently MGMT promoter methylated. Among pediatric-type tumors, the incidence rate was 0.06 for H3K27M-mutant diffuse midline gliomas (95%CI: 0.05-0.07), 0.03 for SHH-activated/TP53-wildtype medulloblastomas (95%CI: 0.02-0.03), and <0.01 for both C19MC-altered ETMRs and RELA-fusion ependymomas. Conclusions Our findings illustrate the success of developing a dedicated, integrated-diagnosis variable, which provides critical molecular information about brain tumors related to accurate diagnosis. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

ONC201 and ONC206: metabolically ClipPing the wings of diffuse midline glioma

alexandrossfakianakis shared this article with you from Inoreader ONC201 and ONC206: metabolically ClipPing the wings of diffuse midline glioma Via Neuro-Oncology Advance Access View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Renal denervation for atrial fibrillation: a comprehensive updated systematic review and meta-analysis

alexandrossfakianakis shared this article with you from Inoreader Renal denervation for atrial fibrillation: a comprehensive updated systematic review and meta-analysis Via Journal of Human Hypertension - Issue - nature.com science feeds Journal of Human Hypertension, Published online: 25 April 2022; doi:10.1038/s41371-022-00700-1 Renal denervation for atrial fibrillation: a comprehensive updated systematic review and meta-analysis View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Effect of vitamin E supplementation in rheumatoid arthritis: a systematic review and meta-analysis

alexandrossfakianakis shared this article with you from Inoreader Effect of vitamin E supplementation in rheumatoid arthritis: a systematic review and meta-analysis Via European Journal of Clinical Nutrition - Issue - nature.com science feeds European Journal of Clinical Nutrition, Published online: 25 April 2022; doi:10.1038/s41430-022-01148-9 Effect of vitamin E supplementation in rheumatoid arthritis: a systematic review and meta-analysis View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Higher Moments Matter for Optimal Balance Weighting in Causal Estimation

alexandrossfakianakis shared this article with you from Inoreader Higher Moments Matter for Optimal Balance Weighting in Causal Estimation Via Epidemiology - Published Ahead-of-Print We expand upon a simulation study that compared three promising methods for estimating weights for assessing the average treatment effect on the treated for binary treatments: generalized boosted models, covariate-balancing propensity scores, and entropy balance. The original study showed that generalized boosted models can outperfo rm covariate-balancing propensity scores, and entropy balance when there are likely to be non-linear associations in both the treatment assignment and outcome models and when the other two models are fine-tuned to obtain balance only on first-order moments. We explore the potential benefit of using higher-order moments in the balancing conditions for covariate-balancing propensity scores and entry balance. Our findings showcase that these two models should, by default, include higher order moments and focusing only on first moments can result in substantial bias in estimated treatment effect estimates from both models that could be avoided using higher moments. We expand upon a simulation study that compared three promising methods for estimating weights for assessing the average treatment effect on the treated for binary treatments: generalized boosted models, covariate-balancing propensity scores, and entropy balance. The original study showed that generalized boosted models can outperform covariate-balancing propensity scores, and entropy balance when there are likely to be non-linear associations in both the treatment assignment and outcome models and when the other two models are fine-tuned to obtain balance only on first-order moments. We explore the potential benefit of using higher-order moments in the balancing conditions for covariate-balancing propensity scores and entry balance. Our findings showcase that these two models should, by default, include higher order moments and focusing only on first moments can result in substantial bias in estimated treatment effect estimates from both models that could be avoided using higher mom ents. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Prospective Study of PET/MRI Tumor Response During Chemoradiotherapy for Patients With Low-risk and Intermediate-risk p16-positive Oropharynx Cancer

alexandrossfakianakis shared this article with you from Inoreader Prospective Study of PET/MRI Tumor Response During Chemoradiotherapy for Patients With Low-risk and Intermediate-risk p16-positive Oropharynx Cancer Via American Journal of Clinical Oncology - Current Issue Objective: The objective of this study was to examine tumor response with positron emission tomography (PET)/magnetic resonance imaging (MRI) during chemoradiotherapy as a predictor of outcome in patients with p16-positive oropharynx cancer. Materials and Methods: Patients with p16-positive oropharynx cancer were treated with chemoradiotherapy. Low-risk (LR) disease was defined as T1-T3 and N0-2b and ≤10 pack-years and intermediate-risk (IR) disease as T4 or N2c-3 or >10 pack-years. Patients underwent a PET/MRI scan pretreatment and at fraction 10. Change in value of imaging means were analyzed by analysis of variance. K-means clustering with Euclidean distance functions were used for patient clustering. Silhouette width was used to determine the optimal number of clusters. Linear regression was performed on all radiographic metrics using patient and disease characteristics. Results: Twenty-four patients were enrolled with 7 LR and 11 IR patients available for analysis. Pretreatment imaging characteristics between LR and IR patients were similar. Patients with LR disease exhibited a larger reduction in maximum standardized uptake value (SUV) compared with IR patients (P View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Short-term ADT and Dose-escalated IMRT in Patients With Intermediate-risk Prostate Cancer: Benefit or Caution?

alexandrossfakianakis shared this article with you from Inoreader Short-term ADT and Dose-escalated IMRT in Patients With Intermediate-risk Prostate Cancer: Benefit or Caution? Via American Journal of Clinical Oncology - Current Issue Objectives: In the era of dose-escalated prostate radiation therapy (RT), the use of androgen deprivation therapy (ADT) is undefined for intermediate-risk (IR) prostate cancer. There is growing concern of the risk of ADT to be detrimental to quality of life. This single-institution retrospective analysis aimed to evaluate outcomes of IR patients treated with dose-escalated intensity modulated radiation therapy (IMRT) with or without concurrent/adjuvant short-term ADT. Materials and Methods: Data was collected from 260 consecutive patients treated with dose-escalated IMRT with daily image-guided RT for newly diagnosed IR prostate cancer. Biochemical recurrence-free survival (BCRFS), distant metastasis-free survival, prostate cancer-specific survival, and overall survival (OS) were calculated using Kaplan-Meier methodology. Results: Median follow-up was 93 months. A total of 181 patients had unfavorable IR disease, and 36.2% (N=94) received ADT, with median ADT duration of 6 months. Seven-year BCRFS was 94.1% vs. 86.2% (P=0.067), for ADT and no ADT, respectively, and no difference in distant metastasis-free survival or prostate cancer-specific survival was observed. ADT was associated with significantly worse 7-year OS (80.0% vs. 91.3%, P=0.010). Analysis of the unfavorable IR cohort alone, showed similar results; 7-year BCRFS and 7-year OS in patients who received ADT versus no ADT were 93.7% vs. 85.9% (P=0.093), and 79.0% vs. 90.6% (P=0.019), respectively. Conclusions: In our 15-year experience treating IR prostate cancer with dose-escalated IMRT with daily image-guided RT, short-term concurrent ADT was associated with a statistically significant worse OS. Additional studies are needed to determine if ADT is beneficial or detrimental for patients with IR prostate cancer treated with dose-escalated radiation. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.